Hepatitis C News and Research

Latest Hepatitis C News and Research

Experimental drugs offer hope for people with hepatitis C

Patrizia Cazzaniga had heard the horror stories about early treatments for hepatitis C - multiple daily pills and weekly shots for up to a year, side effects that could be debilitating, and a cure rate of only about 40 percent.

11 Mar 2014

First Edition: March 10, 2014

Today's headlines include reports about how the Virginia Assembly's impasse on Medicaid expansion is playing out.

10 Mar 2014

Longer looks: Health care in jail; preventing Medicare drug fraud; new medical codes

"Sheriff Ashe," [the waitress] began. "My daughter is in your jail." She then told me her daughter's story. "Laura," as I'll call her here, was a bright and sociable girl who, after graduating from high school, went on to community college.

10 Mar 2014

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Today Boehringer Ingelheim announced results from STARTVerso4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg faldaprevir dose groups.

6 Mar 2014

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012.

6 Mar 2014

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals.

6 Mar 2014

New study uses Lumosity games to detect subtle cognitive impairments in patients with cirrhosis

A new study from the University of Washington has found that performance on Lumosity games can distinguish between patients with cirrhosis of the liver, pre-cirrhotic patients, and healthy controls. The study used Lumosity games as psychometric tests to detect subtle cognitive impairments in patients with cirrhosis. The study is published in the March issue of the American Journal of Gastroenterology.

6 Mar 2014

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.

5 Mar 2014

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

The first detailed results from AbbVie's pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4.

4 Mar 2014

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection.

4 Mar 2014

Costly new hepatitis C drug raises questions about who will pay

The new hepatitis C medication presents a dilemma for Medicaid and other insurers, who must balance the cost against the large numbers of people who might benefit. A single course of treatment costs $84,000.

4 Mar 2014

First Edition: March 3, 2014

Today's headlins include stories detailing ongoing challenges with state-run exchanges as well as previews of what's next regarding the federal budget process.

3 Mar 2014

Longer looks: A doctor struggles with new health system; how to reduce end-of-life costs; fighting cancer with aspirin

I know how lucky I am to be a patient who happens to also work in the healthcare system. ... Initially, I had to use antibiotic drops every hour. But my insurance would only cover one three-milliliter bottle every three weeks. Each bottle not covered by insurance cost me $130. ... My own experience makes me fear that for many Americans, health insurance may not necessarily equal health care. Access and cost will still remain barriers-;and can be difficult to surmount for many (Dr. Helen Ouyang, 2/24)

28 Feb 2014

Waiting room time helps in effective screening for depression and anxiety

A new study in General Hospital Psychiatry finds patients visiting the hospital for a variety of ailments can be easily screened for depression and anxiety as they wait for care, information that can then be sent immediately to their doctor to address.

27 Feb 2014

Researchers discover new target for human antibodies that holds key to vaccine for dengue

Creating a vaccine that protects people from all four types of dengue virus has frustrated scientists for decades. But researchers at the University of North Carolina have discovered a new target for human antibodies that could hold the key to a vaccine for the world's most widespread mosquito-borne disease.

27 Feb 2014

UNC receives $40M for clinical trials unit devoted to HIV/AIDS treatment, prevention and research

The University of North Carolina at Chapel Hill has received a seven-year, more than $40 million award from the National Institutes of Health for a clinical trials unit that will implement the scientific agendas of five NIH networks devoted to HIV/AIDS treatment, prevention, and cure research.

27 Feb 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Scientists discover how viral DNA of HBV can be degraded in cell nucleus

Scientists from the Helmholtz Zentrum München and the Technische Universität München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing the virus to be eliminated.

24 Feb 2014

People suffering from schizophrenia at greater risk of developing autoimmune diseases

Researchers have long known that people with autoimmune diseases, such as hepatitis, type 1 diabetes, multiple sclerosis and psoriasis, are at greater risk of developing schizophrenia.

24 Feb 2014

Social/behavioral intervention strategies may help drug users avoid injection-related HCV, HIV infections

Despite a number of social/behavioral intervention and educational programs, the spread of hepatitis C (HCV) in people who inject drugs (PWIDs) remains a chronic problem.

24 Feb 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

Experimental drugs offer hope for people with hepatitis C

First Edition: March 10, 2014

Longer looks: Health care in jail; preventing Medicare drug fraud; new medical codes

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

New study uses Lumosity games to detect subtle cognitive impairments in patients with cirrhosis

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Costly new hepatitis C drug raises questions about who will pay

First Edition: March 3, 2014

Longer looks: A doctor struggles with new health system; how to reduce end-of-life costs; fighting cancer with aspirin

Waiting room time helps in effective screening for depression and anxiety

Researchers discover new target for human antibodies that holds key to vaccine for dengue

UNC receives $40M for clinical trials unit devoted to HIV/AIDS treatment, prevention and research

FDA approves KALYDECO for people with cystic fibrosis

Scientists discover how viral DNA of HBV can be degraded in cell nucleus

People suffering from schizophrenia at greater risk of developing autoimmune diseases

Social/behavioral intervention strategies may help drug users avoid injection-related HCV, HIV infections

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in